GeneralBreaking NewsBreakingLatest News
Cancer Drugs See Up to 93% Price Cuts, Keytruda Prices Remain Unchanged
Sentiment: NeutralHigh Priority
What Happened?
India's drug price regulator has slashed the maximum retail prices of 543 cancer drugs by over 90% for some brands. However, Keytruda, a leading cancer treatment, remains at Rs 2,16,500.
Key points
- The NPPA revised prices for 543 cancer drug brands, with some reductions exceeding 90%.
- Palbociclib's price dropped from Rs 40,421 to Rs 2,720, a 93.3% reduction.
- Keytruda's price remains unchanged at Rs 2,16,500 despite the revisions.
- The new prices will take effect on November 9, capping trade margins at 30% for certain drugs.
- The Supreme Court is reviewing the government's approach to high cancer drug prices.
Key insights
- The unchanged price of Keytruda highlights ongoing challenges in making cancer treatments affordable.
- Patients may still face high costs despite price reductions for many drugs.
- The Supreme Court's potential intervention could lead to broader changes in drug pricing policies.
Why it matters
The price cuts could significantly reduce the financial burden on cancer patients in India.
Tags
Entities
Keytruda· ProductNPPA· OrganizationIndia· Country
Source
India Today
